光遗传学技术在酪氨酸受体激酶等靶向药物筛选中的应用  

Application of optogenetics-based targeted drug screening for receptor tyrosine kinases and beyond

作　　者：郭丽莎 魏夏瑜 李校堃 张金三[1,2,3] GUO Lisha;WEI Xiayu;LI Xiaokun;ZHANG Jinsan(School of Pharmaceutical Science,Wenzhou Medical University,Wenzhou 325035,China;School of Environmental and Life Sciences,Wenzhou University,Wenzhou 325035,China;Center for Precision Medicine,The First Affiliated Hospital,Wenzhou Medical University,Wenzhou 325035,China)

机构地区：[1]温州医科大学药学院,温州325035 [2]温州大学生命与环境科学学院,温州325035 [3]温州医科大学附属第一医院精准医学中心,温州325035

出　　处：《生物产业技术》2018年第5期97-103,共7页Biotechnology & Business

基　　金：自然科学基金项目(81472601);温州医科大学及温州大学科研启动经费

摘　　要：光遗传学的发明为神经科学领域带来重大突破,相关技术使对蛋白质功能调控、信号通路激活及动物行为的时空精确控制成为可能,为研究神经回路及信号网络提供了独特的手段。近年来,光遗传学技术与相关报告基因结合被应用到药物筛选平台。该平台利用光信号代替电生理或其他试剂(如生长因子等),激活细胞的受体激酶或离子通道,具有高通量、操作简便及低成本等特点。对光控基因工程技术作为受体酪氨酸激酶的研究手段及新的靶向药物筛选平台进行总结。The invention of optogenetics has brought about a major breakthrough in the field of neuroscience. Related technologies have made it possible to control protein function, signal pathway activation and spatial-temporally control of animal behavior, providing a unique way for studying neural circuits and signal networks. Recently, optogenetics technology and related reporter genes have been applied to drug screening platforms. The platform uses optical signals instead of electrophysiological or other reagents, such as growth factors, to activate receptor kinases or ion channels in cells, with high throughput, ease of operation, and low cost. In this paper, light-control genetic engineering technology as a research tool for receptor tyrosine kinase and a new targeted drug screening platform are summarized.

关 键 词：光遗传学 受体酪氨酸激酶 靶向药物筛选平台 

分 类 号：R965.1[医药卫生—药理学]